Today: 20 November 2025
Subscribe
Browse Category

AI in Healthcare News 17 July 2025 - 5 November 2025

Recursion Pharmaceuticals (RXRX) – AI Drug Discovery Breakthroughs, CEO Shakeup & 2025 Stock Outlook

Recursion Pharmaceuticals (RXRX) – AI Drug Discovery Breakthroughs, CEO Shakeup & 2025 Stock Outlook

Below we dive into a detailed analysis of RXRX – covering the latest developments, the company’s AI-powered business model, financials, key partnerships, expert commentary, technical trends, forecasts, and how Recursion compares to other AI-focused biotech players. Latest Developments and News (Early November 2025) Q3 2025 Earnings & Milestone: Recursion’s third-quarter 2025 report (released Nov 5) was a mixed bag. The company posted quarterly revenue of $5.2 million, a steep drop from $26.1 million in Q3 last year stocktitan.net. This was a significant miss versus Wall Street’s ~$17 million forecast, reflecting the lumpy nature of partnership payments (no big milestone was booked as revenue in
5 November 2025
 ·  ·  ·  ·  · 
AI Just Diagnosed You—Now What? The Rise of Superhuman Doctors Made of Code

AI Just Diagnosed You—Now What? The Rise of Superhuman Doctors Made of Code

A boy in the United States with three years of chronic pain was diagnosed by an AI chatbot with spina bifida occulta, later confirmed by a specialist. Microsoft’s AI Diagnostic Orchestrator (MAI-DxO) achieved an 85% correct diagnosis rate on nearly 300 challenging NEJM case studies, compared with 20% for 21 experienced physicians, while ordering 20% fewer tests. Google’s conversational diagnostic AI prototype outperformed physicians on hypothetical primary care cases, scoring about 59% accuracy versus 33% for human doctors. PathAI announced a major 2024 partnership with Quest Diagnostics, with Quest acquiring PathAI’s laboratory and integrating AI across its pathology labs. IDx-DR
29 July 2025
 ·  ·  ·  · 
AI Pathology Breakthrough: Roche’s Lung Cancer Diagnostic Makes FDA History

AI Pathology Breakthrough: Roche’s Lung Cancer Diagnostic Makes FDA History

In April 2025, Roche’s Ventana TROP2 (EPR20043) RxDx test became the first AI-powered diagnostic to receive FDA Breakthrough Device Designation. The device pairs an immunohistochemistry stain for TROP2 with a digital pathology AI algorithm that runs in Roche’s Navify system to analyze NSCLC biopsy slides. The AI calculates a Normalized Membrane Ratio (NMR), the ratio of surface TROP2 to internal TROP2, to classify tumors as TROP2-positive or -negative. The Ventana TROP2 RxDx is a full diagnostic system, including Roche’s slide scanners, the Navify image management software, the Ventana TROP2 IHC kit, and the AI algorithm. A positive NMR score thresholds
17 July 2025
 ·  ·  ·  ·  ·  · 
Go toTop